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Corticosteroids (oral or inhaled) are commonly used to treat pulmonary sarcoidosis; however,
there is no consensus about when to start treatment, what dose of steroids to give and for how
long. Immunosuppressive and cytotoxic agents (used in immunosuppressive doses) are used in
addition to oral corticosteroids to treat multisystem and chronic sarcoidosis, or as steroid-
sparing agents. We summarize the findings from two Cochrane systematic reviews that have
examined the efficacy of corticosteroids and immunosuppressive and cytotoxic drugs in the
treatment of pulmonary sarcoidosis. Studies of corticosteroids differed in outcome measures,
dose of drug given and length of treatment. For many outcome measures, data could not be
pooled for meta-analysis. Oral corticosteroids improved chest X-ray appearance over 3–24
months, with improvement in global score in one study. Little evidence was found of
improvement in lung function or of any long-term disease-modifying effect. Follow-up data
could not be analysed. Inhaled corticosteroids improved symptoms in one small study but not
lung function or chest X-ray. Side-effects of steroids were not well reported. In the
immunosuppressive and cytotoxics review, no data could be combined for meta-analysis. Data
on lung function, chest X-ray and dyspnoea were largely inconclusive. Methotrexate had a
steroid-sparing effect in one small study. Significant adverse events were associated with
cyclosporine A, chloroquine and pentoxifylline. Evidence from randomized-controlled trials
(RCTs) supporting the use of immunosuppressive and cytotoxic agents is limited.
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Sarcoidosis is a common multisystem granulomatous disease
that frequently involves the lungs and can result in
pulmonary fibrosis. Certain populations have a higher
incidence of the disease, and the course of the disease is
more relentless, with higher mortality and morbidity.1 The
severity of lung involvement is assessed on the basis of
symptoms (particularly dyspnoea and cough), changes on
chest X-ray (staged from 1 to 4) and lung function. Patients
may also complain of systemic symptoms such as lethargy
and organ-specific symptoms.
Oral and inhaled corticosteroids are used widely to treat
pulmonary sarcoidosis, but there is no consensus about when
treatment should be started, what dose of steroids should
be given and for how long. Corticosteroids are given to
reduce symptoms and to minimize long-term effects of the
disease. Immunosuppressive and cytotoxic drugs are also
given to patients with multisystem sarcoidosis in order to
minimize symptoms in chronic sarcoidosis and as steroid-
sparing agents. Combinations of drugs are often given. All
drugs, including oral corticosteroids, have significant side-
effects, particularly when given over a long period of time,
and careful monitoring of the patient is required.
Sarcoidosis runs an unpredictable course: spontaneous
resolution can occur without treatment2 and relapses can
also occur. Studies in sarcoidosis should take this into
account and also that steroid responsiveness may vary by
baseline severity. Randomization, blinding and adequate
allocation concealment are all important in trials in order to
minimize bias, but may not be done well, or even reported
in trials. Trials need to ensure that treatment and control
groups share the same baseline characteristics and that
there is a control arm. Many trials have failed to do this.In this paper, we provide an overview of the evidence
from randomized-controlled trials (RCTs) on the efficacy of
corticosteroids (oral and inhaled) and immunosuppressive
and cytotoxic drugs in the treatment of pulmonary
sarcoidosis. This overview is based on separate reviews
published in the Cochrane Library.3,4
Review methodology
Study inclusion criteria
Reviews included RCTs of adults with evidence of pulmonary
sarcoidosis, judged where possible on histological evidence.
Patients with other interstitial lung diseases were excluded.
Trials looking primarily at non-pulmonary manifestations of
sarcoidosis were not considered; patients with multisystem
sarcoidosis and lung involvement were considered eligible.
Interventions
In the corticosteroid systematic review,3 trials compared
participants taking oral or inhaled corticosteroids with
controls receiving placebo or no treatment (Table 1). In
the immunosuppressives and cytotoxics review,4 the treat-
ment groups received chloroquine, methotrexate, cyclos-
porine A or pentoxifylline. The control groups received
corticosteroids alone, placebo alone or placebo and corti-
costeroids (Table 2). No RCTs using azathioprine, hydroxy-
chloroquine, chlorambucil, cyclophosphamide, tumour
necrosis factor alpha (TNFa) or thalidomide were identified.
Outcome measures
Primary outcome measures were chest X-ray changes, lung
function measurements (forced expiratory volume in 1 s
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Table 1 Details of included studies in the systematic review of corticosteroids in pulmonary sarcoidosis.3
Source (year) Disease
stage
Treatment arms Sex Age range
(years)
Follow-up
after
treatment
Allocation
conceal-
ment
Study
quality
(Jadad
score)
Active Control Treatment
duration
Alberts et al.7 1–3 Budesonide, 1.2mg/day Placebo 6 months 21 male
26 female
20–65 6 months A 4
Baughman
et al.8
1–4 Prednisone then fluticasone 880mcg/day Placebo 12 weeks 8 male
14 female
22–64 48 weeks B 3
DuBois et al.9 2–3 Fluticasone, 2mg/day (75% on oral steroids) Placebo 6 months 17 male
26 female
18–65 None B 3
Erkkila et al.10 1–2 Budesonide, 0.8mg twice a day Placebo 8–10 weeks 8 male
11 female
27–59 None B 3
Israel et al.11 1–3 Prednisone, 15mg/day Placebo 3 months 23 male
60 female
21–40 1–11 years B 3
James et al.12 Multisys-
tem
Prednisolone, 20mg/day Placebo 6 months 42 male
33 female
0–60 None A 4
Ludwig-Sengpiel
et al.13
1–3 BDP, 800mcg/day Placebo 12 weeks 9 male
6 female
35 (mean) None B 5
McGrath et al.14 2–4 HFA-134a BDP, 1.6mg/day Placebo 6 months 11 male
20 female
18–65 3 months B 3
Milman et al.15 1–3 Budesonide, 1.2/2mg/day eight patients on oral
steroids
Placebo 12 months 17 male
5 female
21–65 18 months B 3
Pietinalho
et al.16
1–2 Prednisolone, 10–20mg for 3 months then budesonide,
1.6mg for 15 months
Placebo 18 months 105 male
84 female
Not stated 18 months B 3
Roth et al.17 1–3 40mg prednisone then reduced by 5mg/day No
treatment
12 months
or 6 months
(two groups)
87 male
85 female
20–69 3–14 years B 1
Selroos and
Sellergren18
2 Methylprednisolone, 4–32mg No
Treatment
7 months 19 male
18 female
Not stated 4 years B 1
Zaki et al.19 1–3 Prednisone, 40mg for 3 months, then 20mg Placebo 2 years 25% male
75% female
All 2–4 years B 3
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Table 2 Details of included studies in the systematic review of immunosuppressive and cytotoxic therapy in pulmonary
sarcoidosis.4
Source (year) Disease
stage
Treatment arms Treatment
duration
Sex Age range
(years)
Follow-up
after
treatment
Allocation
conceal-
ment
Study
quality
(Jadad
score)
Active Control
BTA22 2–4 Chloroquine 600mg/day
(8 weeks), 400mg/day
(8 weeks)
Placebo 4 months 21 female
31 male
n ¼ 52
All ages 8 months A 4
Wyser et al.24 1–4 Cyclosporine A
(7mg/kg/day)+
declining doses of
prednisone
Prednisone 6 months 24 female
13 male
n ¼ 37
Mean Age
37
18 months B 2
Baltzan
et al.20
2,3 Chloroquine
(250mg/day)
Placebo 6 months 10 female
8 male
n ¼ 18
29–67 19.7
months
(6–48)
B 3
Baughman
et al.21
1–3 Methotrexate
(10mg/day)+
prednisone
(40mg/day)
Placebo+
prednisone
(40mg/day)
12 months 10 female
14 male
n ¼ 24
26–52 None B 5
Manganiello
et al.23
Not
reported
Pentoxifylline
(unspecified
dose)+corticosteroids
Placebo+cor-
ticosteroids
24 weeks Not
reported
n ¼ 27
18–70 Not
reported
B 2
S. Paramothayan, T. Lasserson4[FEV1], forced vital capacity [FVC], inspiratory vital capacity
[IVC], diffusing capacity of carbon monoxide [DLCO] and
diffusing capacity of carbon monoxide corrected for lung
volume [DLCO/VA]) and steroid usage. Secondary outcomes
were symptoms, adverse events and mortality. Outcome
measures varied from trial to trial.
Literature search and identification of trials
Searches were carried out using MEDLINE, EMBASE, CINAHL
and the Cochrane Controlled Trials Register of 218,352 RCTs
up to May 2006 using pre-defined terms.
Methods of the review
Bibliographies of review articles and RCTs were searched for
additional RCTs, and pharmaceutical companies and authors
of RCTs were contacted for additional data and other
published and unpublished studies. All studies, irrespective
of language, were assessed by two reviewers to ensure they
met the inclusion criteria. A third reviewer was to intervene
if disagreement occurred, but none occurred. Each study
was assessed, using pre-specified criteria, for the reliability
of the diagnosis of sarcoidosis.
Statistical analyses
Where possible, trial data were combined with Review
Manager version 4.2 (Revman, The Cochrane Collaboration,
Oxford, England). Continuous data (data measured by scales
such as symptom scores) were aggregated to generate
weighted mean differences. Dichotomous data (end points
that divide study participants into two groups such as‘improved’ or ‘not improved’) were combined as a ratio of
odds (OR). We measured statistical variation between the
studies using the I2-statistic,5 which expresses in percentage
terms the amount of variation between the trials over and
above what would be expected by chance. Planned subgroup
analyses included corticosteroid dose, disease stage and
disease duration. Data from trials looking at different drugs
were analysed separately.
Study quality
For each trial, the concealment of allocation and the overall
methodological quality using the five-point Jadad score6
(which evaluates the reporting quality of randomization,
blinding and withdrawal) were assessed by two reviewers.
Description of studies
Corticosteroid review
In the corticosteroid review,3 150 citations were identified,
with 13 RCTs of variable quality included. Authors were
contacted for verification of methodological quality, rando-
mization procedure and information on outcome data.
Three responded with additional information. All included
studies were randomized; methods of randomization were
reported in three studies.7,11,18 Eleven studies were double-
blind but two17,18 had a ‘no treatment’ control arm and
one17 recruited participants on an open-ended basis over 10
years. A total of 1066 participants were recruited; median
sample size was 45 (range: 15–280). All participants were
adults with pulmonary sarcoidosis; most were white males.
Diagnosis of sarcoidosis was based on chest X-ray and
ARTICLE IN PRESS
Treatments for pulmonary sarcoidosis 5histology in all studies but one.18 Three studies8–10 used
participants with newly diagnosed sarcoidosis, and the
others included disease of longer duration. Chest X-ray
staging at baseline and primary end points varied between
studies. All studies reported data on lung function; all
except one8 reported data on chest X-ray.
Three studies compared oral corticosteroids with place-
bo,11,12,19 two studies compared oral corticosteroids with a
control group on no treatment,17,18 six studies compared
inhaled corticosteroids with placebo,7,9,10,13–15 and one
study compared inhaled corticosteroids with placebo as oral
corticosteroid sparing agent.8 In two studies on inhaled
corticosteroids,9,15 some participants had received prior
treatment with oral corticosteroids. One study16 compared
inhaled corticosteroid with placebo after oral corticosteroid
versus placebo: participants randomized to oral corticoster-
oids received inhaled corticosteroids, and those randomized
to oral placebo received inhaled placebo. Data could only be
pooled for the first treatment period (oral corticosteroid vs.
placebo) (Table 1).
Immunosuppressives and cytotoxics review
In the immunosuppressives and cytotoxics review,4 502
studies were identified by the search, but only five RCTs
were identified, containing a total of 164 participants.
Studies were small, with sample sizes ranging from 2420,21 to
52.22 Pulmonary sarcoidosis was diagnosed histologically in
all studies except one.22 Trials were randomized with a
parallel group design. Four studies were double-blind20–23
and one24 an open label study.
Four different treatments were assessed in the five studies
(Table 2). Two studies20,22 had the control groups on placebo
alone, two studies21,23 had the control groups on placebo plus
corticosteroids, and one study24 had the control group on
corticosteroids. Study duration varied from 1622 to 24
weeks.23 The average follow-up period was 19.7 months
(6–48 months). In three studies,21,23,24 participants were
taking oral corticosteroids. The process by which corticoster-
oid dose was reduced was well reported in two studies,21,24
but not in one study.23 Two studies20,22 assessed chloroquine
treatment without concomitant corticosteroid therapy.
Outcomes
Chest X-ray findings and symptoms were reported in two
studies22,24 and lung function reported in all except one.23 Two
studies21,23 reported the effect of treatment on concurrent
corticosteroid use. All studies reported adverse events (Table 2).
Methodological quality of included studies
Corticosteroid review. See Table 1 for Jadad scores and
Cochrane allocation concealment grades.3 The differences
in Jadad scores reflect differences in quality of reporting
rather than in the methodological quality of the studies.
Studies were of variable quality. Verification of randomiza-
tion procedure was available for three studies.11,13,18 In two
studies,17,18 the control group had no treatment; in the
absence of adequate blinding, this may have distorted any
treatment effect.
Immunosuppressives and cytotoxics review. See Table 2 for
Jadad scores and Cochrane allocation concealment grades.4The overall quality of the studies was mixed. Details of
intervention varied between studies; description of control
arm was unclear in one study,20 with no placebo arm in
another study24; so blinding could not have fully occurred.
Randomization procedures were not reported in any
of the published papers but established following corre-
spondence for one study.21 Two studies were of high
quality.21,22 One study22 obtained an allocation concealment
grading of A, but the ages of participants at baseline
differed significantly between the two groups: this was
attributed to chance. One study23 was an unpublished
conference abstract of low quality with limited information.
Withdrawals and drop-outs were well reported in all studies
except one.23 In one study,21 the profile of each patient that
withdrew from the trial was reported along with the reason
for doing so.Results
Corticosteroid review
Oral steroids versus placebo
On the basis of data from the three studies that could be
combined,12,16,19 a significant improvement in chest X-ray
was found in the group treated with oral corticosteroids
compared with the placebo group. The fixed-effects OR was
2.46 (95% confidence interval 1.59–3.79; Po0.001); the
random effects OR was 2.68 (95% CI 1.25–5.76) (Figure 1).
More patients in the control group had unchanged
chest X-ray at the end of treatment compared with
the group on oral corticosteroids. Patients in the control
group had a significantly greater deterioration in chest
X-ray compared with the group taking oral corticosteroids
(OR 0.33; 95% CI 0.14–0.81). However, there was moderate-
to-high inconsistency between the studies (I2 60.9%).
The duration of treatment varied between the
studies (3–24 months), and may account for differences in
response.
Two studies of low methodological quality17,18 had control
groups on no treatment, so results could not be combined
with trials above. One small study18 reported improvement
in chest X-ray at 7 months in the corticosteroid group, but,
by 24 and 48 months, this difference was no longer
significant.
One study11 recorded a global score of chest X-ray
changes, lung function and symptoms (grouped together as
a global outcome in an unspecified manner) in 83 patients,
and showed an improvement with oral corticosteroids after
3 months compared with the control group. Sub-group
analysis showed improvement in global score with Stage 2
and 3 disease but not Stage 1 disease. No significant
difference was found between the treated and control
groups in the number of patients whose global scores
remained unchanged or deteriorated.
Results of lung function data from different studies16,18,19
could not be combined. In one study of 159 patients treated
with oral corticosteroids for 2 years, no significant differ-
ences were found in any measure of lung function (FEV1, FVC
and DLCO as dichotomous data) between treated and
placebo groups.19 Subgroup analysis of the radiographic
stages showed no differences. Two studies16,18 measured
ARTICLE IN PRESS
Figure 1
S. Paramothayan, T. Lasserson6FVC and DLCO as continuous data. In the small study of poor
quality with no control arm,18 there was an improvement in
FVC and DLCO with corticosteroids. Symptoms were not
reported in any of these studies on oral corticosteroids
versus placebo.Inhaled steroids versus placebo
In four studies, patients had received no oral corticosteroids
before receiving inhaled corticosteroids.7,10,13,14 In three
studies9,15,16 a significant number of patients had received
oral corticosteroids either as prior treatment or as part of
the study protocol. Because data on chest X-ray and lung
function were presented for all participants, regardless of
whether participants had been treated with oral corticos-
teroids before study entry or not, the data from these
studies could not be pooled.
No significant differences were found in chest X-ray
between inhaled corticosteroids and placebo in three
studies.10,13,14 (Figure 1). Chest X-ray results from one
study7 could not be analysed. Inaccurate numbers were
reported and no verification of data has been obtained.
Data on FEV1 and DLCO (% predicted) pooled from
three small studies10,13,14 and measurement of IVC (as %
and litres) from two studies7,13 showed no statistically
significant differences between treated and control
groups. One small study10 measured DLCO/VA (as dichot-
omous data) in 19 patients at the end of treatment
with inhaled corticosteroids for 8–10 weeks and
showed a significant improvement (+15%) in the treated
group.
One study7 found an improvement in the global clinical
index (which included symptoms) in the treated group
compared with placebo. Two studies9,15 did not present data
on symptoms separately for participants who had not
received steroids before trial entry. No significant differ-
ences in symptoms were reported in any other study.Inhaled steroids versus placebo as oral steroid-sparing
agent
No data were presented on changes in chest X-ray.8 No
significant differences in FVC between treated and control
groups were found. Median change in exercise capacity was
reported but no details of the significance level were
provided. No statistically significant differences were found
between the fluticasone and placebo groups in any measure
of symptom or in requirement for oral corticosteroids.
Several trials did not report adverse effects or corticos-
teroid-induced complications. It was not clear how pro-
spective monitoring or patient self-report collected the data
(Table 3).
Summary of results at follow-up
Treatment duration varied between studies, from 8 weeks10
to 2 years.19 Seven RCTs followed patients for 1–14 years
from the end of the randomized-controlled period (Table 1).
Data on chest X-ray changes, lung function, and symptoms
were recorded but not reported in a systematic manner and
could not be aggregated. No statistically significant differ-
ence in any outcome was shown in any study at the end of
the follow-up period. Patients with improvement in chest
X-ray, symptoms, global scores or lung function at the end of
the treatment period did not maintain this improvement,
relative to the control group, at follow-up. There was no
standardized data collection after a period of corticosteroid
withdrawal in any study.
Immunosuppressive and cytotoxics review
RCTs using methotrexate,21 chloroquine,20,22 cyclosporine
A24 and pentoxifylline23 were identified. No data could be
combined for meta-analysis (different drugs and end
points). Data on lung function, chest X-ray scores and
dyspnoea were largely inconclusive. Much of the data on
medication usage and lung function were reported as
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Table 3 Details of patients randomized, excluded, withdrawn and lost to follow-up and reported adverse effects in the systematic review of corticosteroids in pulmonary
sarcoidosis.3
Source (year) Number of patients
Randomized Completed Excluded Withdrawn Lost to follow-
up
Total withdrawn or lost to
follow-up
Reasons Adverse effects
Alberts et al.7 47 40 0 6 1 Budesonide group (4)
Placebo group (3)
Five withdrew consent (two
required oral prednisolone), one
withdrew due to intercurrent
disease
No budesonide related adverse events
reported
Baughman et al.8 22 19 0 2 1 Placebo (2) Fluticasone (1) Dropped out No significant adverse events reported
DuBois et al.9 43 34 4 6 0 Fluticasone group (4)
Placebo group (2)
Four excluded because of lack of
diary card data; six withdrew due to
serious adverse events; no
explanation for discrepancy in
numbers
Adverse events reported: fluticasone,
18/21 patients; placebo, 19/22
patients; chest infections, ‘asthma’,
skin rash, hoarseness
Erkkila et al.10 19 18 0 1 0 Budesonide group (1) Adverse events in treated group Sensation of swelling of mouth
Israel et al.11 90 83 0 0 7 7 Not clear why seven patients did not
complete treatment
None described
James et al.12 84 75 0 2 7 Prednisolone group (3)
Oxyphenbutazone group (3)
Placebo group (3)
One pregnant, one given steroids
unintentionally, seven defaulted
Gross fluid retention, cushingoid
changes
Ludwig-Sengpiel et al.13 15 15 0 0 0 0 NA None described
McGrath et al.14 33 27 0 5 1 6 Two withdrew, one lost to follow-up,
three required increase in oral
therapy
Four developed oral candida, one
hoarseness, one ecchymoses and
purpura, one high-blood glucose levels,
two reflux
Milman et al.15 21 17 0 4 0 Budesonide (3), Placebo (1) Side-effects, found device
cumbersome, pregnancy
Cough, sore throat, nausea
Pietinalho et al.16 189 154 0 35 0 Treatment group (16)
Placebo group (19)
Seven withdrew consent, three due
to adverse events, 16 due to
treatment failure, five due to poor
compliance, four due to other
reasons
Adverse events: prednisolone followed
by budesonide (2); placebo (1);
decrease in serum cortisol below
normal range; corticosteroid treated
(11/92); placebo treated (1/97)
Roth et al.17 280 172 0 31 77 108 19 violated protocol; 12 had side-
effects. Not explicit which groups
these participants were allocated to
None described
Selroos and Sellergren18 37 32 2 5 0 All placebo group (5) Two excluded due to non-
compliance, five withdrew due to
symptoms requiring prednisolone
Six developed moonface, seven weight
increase, one hyperglycaemia, four
hypokalaemia and one hypertension
Zaki et al.19 183 159 24 0 0 0 Lack of co-operation, relocation,
concomitant clinical condition, or
death
None described
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S. Paramothayan, T. Lasserson8medians and ranges calculated with use of non-parametric
statistical tests, indicative of uneven distribution. Two
studies reported means and standard deviations on chest
X-ray scores and lung function decline rates, respec-
tively.22,20 No data on mortality or quality of life were
reported. Adverse events were reported in all studies. No
sub-group analysis was possible.
Patients taking methotrexate21 required significantly
lower doses of corticosteroids than placebo after 12 months
of treatment. Steroid usage was the primary end point, and
data were presented as medians and ranges. There was no
significant difference in steroid dose at 6 months between
the groups. After 12 months, both groups required less
prednisone but those on methotrexate required significantly
less prednisone (median 8.3mg/day [0.83–21.7]) than the
control group (median 16mg/day11–22): Po0.001. There was
no difference between the groups in lung function (VC),
symptoms (dyspnoea) or adverse events. No data on chest
X-ray were reported.
Steroid usage and recurrence rate were lower in the
pentoxifylline group23 but with significant side-effects. This
study was small, and randomization and blinding were not
clear (Jadad score 2).
Treatment with cyclosporine A and prednisone was no
better than prednisone alone in measurements of lung
function. There was a statistically significant improvement
in dyspnoea in both groups compared with baseline but no
significant differences between the groups. No data on chest
X-ray were reported. Significant adverse events were
associated with cyclosporine A.24
Chloroquine reduced the decline rate in FEV1 and
DLCO over 20 months in one study
20 but not in another.22
In this study,22 data on lung function were presented
graphically with no distributional data, so could not be
used. There were differences in lung function at baseline
owing to differences in ages of participants in the groups.
No differences were found between the treated and
control groups in chest X-ray scores or dyspnoea at 12
months. Significant adverse events were observed with
chloroquine.Methodological limitations
Few trial data could be combined for meta-analysis: trials on
the effects of corticosteroids used different outcome
measures and presented lung function data in the form of
dichotomous or continuous data. Much of the data
were descriptive; for example, chest X-ray improved,
unchanged or worsened. Oral and inhaled corticosteroid
dose and type of inhaled corticosteroid varied between
studies. Treatment duration varied from 8 weeks10 to 2
years.19 The only sub-group analysis possible was for
radiological stage of disease. Follow-up data, up to a mean
of 8 years after treatment, were available but unusable in
the meta-analysis; follow-up studies were uncontrolled with
no blinding, no common end point, collected data at random
time points, and no information on patients lost to follow-
up. Patients who had deteriorated after the treatment
period were given oral corticosteroids and excluded from
the study. This introduces a selection bias and a survivor
effect, as those who were worst were excluded from the
analysis.A few small trials, of variable quality, using immunosup-
pressive and cytotoxic agents were found. Differences in
treatment or outcome prevented combination of data.
Efficacy was defined as regression of the disease (e.g.
improvement in lung function), no deterioration in the
disease or reduction in the maintenance dose of corticos-
teroids. No long-term follow-up data were available.Discussion
Pulmonary sarcoidosis is characterized by an unpredictable
course, with some patients showing spontaneous resolution,
whereas others progress to lung fibrosis. Overall mortality
from sarcoidosis is 1–5% usually from respiratory, cardiac or
central nervous system disease. Lungs are affected in more
than 90% of patients.25 Because of the natural history of
sarcoidosis, long-term outcome assessment is crucial in
determining whether short-term treatment leads to long-
term benefit.
Treatment of pulmonary sarcoidosis with oral corticoster-
oids for 6–24 months resulted in more patients with
improved chest X-ray and fewer patients with deteriorating
chest X-ray than the placebo group. The risk ratio for
improvement in chest X-ray with oral corticosteroid was
increased by 46% (95% CI: 1–109%), although the dose of
oral corticosteroids varied between studies. Owing to the
lack of controlled trials, there is no evidence that these
improvements are maintained beyond 2 years or that
corticosteroids have a disease-modifying effect. The im-
provement in chest X-ray is seen regardless of radiographic
stage at baseline. A global score that aggregated chest
X-ray, symptoms and lung function improved in the
corticosteroid group; subgroup analysis showed improve-
ment in Stage 2 and 3 disease but not Stage 1 disease.
Pulmonary function data were not reported in a consistent
manner across trials so it was not possible to pool the
results. There was no convincing evidence of improvement
in lung function. Data on other relevant outcomes, such as
respiratory symptoms, exercise tolerance and adverse
events were not reported.
Inhaled corticosteroids did not improve chest X-ray or
lung function but improved global clinical index in one
study.7 As pulmonary sarcoidosis has an endobronchial
component, inhaled corticosteroids may, in theory, improve
symptoms such as cough. Most of the participants in the
trials of inhaled corticosteroids had Stage 1 and 2 disease, so
were perhaps less likely to show a significant improvement.
There was no evidence that inhaled corticosteroids had an
oral corticosteroid-sparing effect.
There is limited RCT evidence to support the use of
immunosuppressive and cytotoxic drugs in pulmonary
sarcoidosis. Most of the published data are anecdotal
and any RCTs have been on small numbers of patients.
Although used in immunosuppressive doses, these drugs
have severe adverse effects and require close monitoring.
One small study21 found that methotrexate has a steroid-
sparing effect after 12 months but with no improvement in
lung function, chest X-ray or symptoms. One small study of
poor quality found that pentoxifylline, a TNFa inhibitor,
reduced steroid usage and recurrence but with severe side-
effects.
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Treatments for pulmonary sarcoidosis 9Practice points
 Patients with Stage 2 and 3 pulmonary sarcoidosis
may benefit from oral corticosteroids for 6–24
months
 Oral corticosteroids are likely to improve chest
X-ray and symptoms
 There is insufficient RCT evidence of any long-term
benefits of oral corticosteroids; steroids should
therefore be withdrawn after this period with
careful monitoring
 There is insufficient RCT evidence that inhaled
corticosteroids are effective in pulmonary sarcoi-
dosis
 There is insufficient RCT evidence to recommend
the use of any immunosuppressive or cytotoxic drug
in pulmonary sarcoidosisResearch directions
 Trials using newer drugs with less severe side-
effects (infliximab, thalidomide, mycophenolate
mofetil, etanercept and leflunimide) need to be
conducted
 In order to recruit sufficient numbers of patients
this is likely to have to be a multi-centre trial
 Trial design must ensure that randomization, blind-
ing and allocation concealment are rigorous and
that the outcome measures include a well-validated
symptom score, lung function and chest X-ray
 Long-term follow-up data, details of withdrawals,
exclusions and adverse events must be reported
 Cochrane reviews are updated regularly. The next
update will include all recent trials and incorporate
those on infliximabAcknowledgements
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